' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Prospective Observational Study Comparing Three Different Treatment Regimes in Patients with Clostridium difficile Infection
Wenisch, JM; Schmid, D; Kuo, HW; Allerberger, F; Michl, V; Tesik, P; Tucek, G; Laferl, H; Wenisch, C
ANTIMICROB AGENTS CH. 2012; 56(4): 1974-1978.
Originalarbeiten (Zeitschrift)



In a hospital-based, prospective cohort study, the effects of the three standard treatment regimens for mild Clostridium difficile infection (CDI), oral (p.o.) metronidazole at 500 mg three times/day, intravenous (i.v.) metronidazole at 500 mg three times/day, and oral (p.o.) vancomycin at 250 mg four times/day, were compared with respect to the risk of occurrence of complications, sequelae, and all-cause death within 30 days after the date of starting treatment. Differences in the incidence of these outcomes were tested by χ² or Fisher"s exact tests. A Poisson regression model was performed to control for possible confounding effects of sex, age, and severity of comorbidity categorized according to the Charlson comorbidity index. The highest mortality was observed in the metronidazole i.v. group, with a mortality rate 38.1% (16/42) compared to mortality rates of 7.4% (9/121) in the metronidazole p.o. group and 9.5% (4/42) in the vancomycin p.o. group (P < 0.001). After adjustment for possible effects of sex, age (> 65 years), and severity of comorbidity, the relative risk of a 30-day fatal outcome for patients receiving metronidazole i.v. was 4.3 (95% confidence interval [CI] = 1.92 to 10; P < 0.0001) compared to patients treated with metronidazole p.o. and 4.0 (95% CI = 1.31 to 5.0; P < 0.015) compared to patients treated with vancomycin p.o. There were no significant differences in the risk of complications between the three treatment groups. This study generates the hypothesis that treatment with i.v. metronidazole is inferior to the oral alternatives metronidazole and vancomycin.

Useful keywords (using NLM MeSH Indexing)

Administration, Oral


Age Factors


Aged, 80 and over

Anti-Bacterial Agents/administration*


Anti-Bacterial Agents/therapeutic use*

Clostridium difficile*

Cohort Studies

Data Interpretation, Statistical

Drug Therapy, Combination

Endpoint Determination

Enterocolitis, Pseudomembranous/drug therapy*

Enterocolitis, Pseudomembranous/microbiology

Enterocolitis, Pseudomembranous/mortality




Injections, Intravenous




Metronidazole/therapeutic use*

Middle Aged

Poisson Distribution

Prospective Studies


Sex Factors

Treatment Outcome



Vancomycin/therapeutic use*

Young Adult